2,163 Labcorp Holdings Inc. $LH Shares Purchased by Illinois Municipal Retirement Fund

Posted by Francis Steltz on Nov 12th, 2026

Illinois Municipal Retirement Fund grew its stake in shares of Labcorp Holdings Inc. (NYSE:LH – Free Report) by 4.5% during the third quarter, Holdings Channel reports. The institutional investor owned 49,854 shares of the medical research company’s stock after buying an additional 2,163 shares during the period. Illinois Municipal Retirement Fund’s holdings in Labcorp were worth $15,361,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently made changes to their positions in the company. Allied Private Wealth LLC bought a new position in shares of Labcorp during the 2nd quarter valued at approximately $33,000. William Mack & Associates Inc. purchased a new stake in Labcorp in the 3rd quarter worth approximately $42,000. Pathway Financial Advisers LLC bought a new stake in Labcorp during the 3rd quarter worth approximately $43,000. Jones Financial Companies Lllp bought a new stake in Labcorp during the 2nd quarter worth approximately $58,000. Finally, Ancora Advisors LLC bought a new stake in Labcorp during the 2nd quarter worth approximately $67,000. 95.94% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts have weighed in on the stock. UBS Group lifted their price target on shares of Labcorp from $380.00 to $420.00 and gave the company a “buy” rating in a report on Thursday, October 29th. Weiss Ratings raised shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a research note on Wednesday, October 21st. Morgan Stanley restated an “overweight” rating and set a $388.00 price objective on shares of Labcorp in a research report on Thursday, October 29th. Robert W. Baird lifted their target price on shares of Labcorp from $361.00 to $396.00 and gave the company an “outperform” rating in a research note on Thursday, October 29th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Labcorp from $330.00 to $360.00 and gave the company an “overweight” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and an average target price of $369.08.

Check Out Our Latest Stock Analysis on LH

Insider Buying and Selling at Labcorp

In other Labcorp news, Director Richelle Parham sold 1,078 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $361.22, for a total transaction of $389,395.16. Following the completion of the sale, the director directly owned 2,288 shares of the company’s stock, valued at $826,471.36. This trade represents a 32.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Bryan Vaughn sold 306 shares of Labcorp stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $353.70, for a total transaction of $108,232.20. Following the sale, the executive vice president owned 6,845 shares in the company, valued at approximately $2,421,076.50. The trade was a 4.28% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 4,384 shares of company stock valued at $1,451,687 in the last three months. 0.84% of the stock is currently owned by corporate insiders.

Labcorp Stock Performance

NYSE LH opened at $371.79 on Thursday. The firm has a market cap of $30.19 billion, a price-to-earnings ratio of 30.50, a price-to-earnings-growth ratio of 2.09 and a beta of 0.86. The company has a quick ratio of 1.22, a current ratio of 1.41 and a debt-to-equity ratio of 0.60. The business has a 50-day moving average price of $328.02 and a 200-day moving average price of $291.56. Labcorp Holdings Inc. has a twelve month low of $245.00 and a twelve month high of $373.76.

Labcorp (NYSE:LH – Get Free Report) last issued its earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.64 by $0.14. The company had revenue of $3.81 billion for the quarter, compared to the consensus estimate of $3.76 billion. Labcorp had a return on equity of 17.13% and a net margin of 6.88%. The firm’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter last year, the company earned $4.18 EPS. As a group, equities research analysts predict that Labcorp Holdings Inc. will post 18.51 EPS for the current fiscal year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend is Tuesday, November 24th. Labcorp’s dividend payout ratio (DPR) is 23.63%.

Labcorp Profile

(Free Report)

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences company that provides diagnostic testing and services to patients, physicians, hospitals, employers and other health care organizations. Its offerings include routine and specialty laboratory tests, anatomic pathology and genetic testing. The company also supports pharmaceutical and biotechnology companies with laboratory services for drug development and clinical trials, including testing and analysis used in research and clinical studies.